Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enobosarm - Veru Healthcare

Next Previous
X
Search
Drug Profile

Enobosarm - Veru Healthcare

Alternative Names: GTx-024; MK-2866; Ostarine; S-22; VERU-024

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ohio State University Research Foundation; University of Tennessee Research Foundation
  • Developer Oncternal Therapeutics, Inc.; Veru Healthcare
  • Class Antineoplastics; Nitriles; Obesity therapies; Small molecules; Urologics
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Obesity
  • Discontinued Cachexia; Duchenne muscular dystrophy; Muscular atrophy; Stress incontinence

Most Recent Events

  • 08 Aug 2024 Veru completes the enrolment from its Phase-II QUALITY clinical trials in Obesity (Adjunctive treatment) in USA (PO) (NCT06282458)
  • 29 Apr 2024 Phase-II clinical trials in Obesity (Adjunctive treatment, In adults, In the elderly) in USA (PO) (NCT06282458)
  • 08 Mar 2024 GTx terminates a phase II trial in Breast cancer (Metastatic disease) in USA (PO) (NCT01616758)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top